Analysis of cerebrospinal fluid of Alzheimer patients: Biomarkers and toxic properties

Pharmacology

Volumn 82, Issue 3, 2008, Pages 214-220

  Marksteiner, Josef ^a   Pirchl, Michael ^a   Ullrich, Celine ^a   Oberbauer, Harald ^a   Blasko, Imrich ^a   Lederer, Wolfgang ^a   Hinterhuber, Hartmann ^a   Humpel, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Alzheimer; Anti nerve growth factor auto antibody; Cerebrospinal fluid; Cholinergic neurons; Nerve growth factor

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CHOLINESTERASE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; PHOSPHOPROTEIN; RECOMBINANT NERVE GROWTH FACTOR; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CEREBROSPINAL FLUID ANALYSIS; CHOLINERGIC NERVE CELL; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

EID: 52049118316     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000156487     Document Type: Article

References (39)

1. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K: Cerebrospinal fluid levels of total-tau, phosphotau and Abeta42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurologica Scandinavica 2003;107:47-51.
2. Desai AK, Grossberg GT: Diagnosis and treatment of Alzheimer's disease. Neurology 2005;64:S34-S39.
3. Fradinger EA, Bitan G: En route to early diagnosis of Alzheimer's disease - are we there yet? Trends Biotechnol 2005;23:531-533.
4. Sjögren M, Andreasen N, Blennow K: Advances in the detection of Alzheimer's disease - use of cerebrospinal fluid biomarkers. Clinica Chimica Acta 2003;332:1-10.
5. Blennow K: CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 2005;5:661-672.
6. Blennow K: CSF biomarkers for mild cognitive impairment. J Intern Med 2004;256:224-234.
7. Humpel C, Blasko I, Marksteiner J, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H: Diagnostik der Alzheimer Demenz und anderere Demenzen in der Cerebrospinalflüssigkeit. Neuropsychiatrie 2005;19:97-101.
8. Zetterberg H, Wahlund LO, Blennow K: Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 2003;352:67-69.
9. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, DeDeyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H: Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-1562.
10. Kurz A, Reimenschneider M, Drzezga A, Lautenschlager N: The role of biological markers in the early and differential diagnosis of Alzheimer's disease. J Neural Transm 2002;62:127-133.
11. Borroni B, Di Luca M, Padovani A: Predicting Alzheimer dementia in mild cognitive impairment patients: are biomarkers useful? Eur J Pharmacol 2006;545:73-80.
12. Barde YA: The nerve growth factor family. Progr Growth Factor Res 1990;2:237-248.
13. Bradshaw RA, Blundell TL, Lapatto R, Mcdonald NQ, Murrayrust J: Nerve growth factor revisited. Trends Biochem Sci 1993;18:48-52.
14. Levi-Montalcini R, Angeletti PU: Nerve growth factor. Physiol Rev 1968;48:534-569.
15. Levi-Montalcini R: The nerve growth factor: thirty-five years later. Bioscience Reports 1987;7:681-699.
16. Thoenen H, Barde, YA: Physiology of nerve growth factor. Physiol Rev 1980;60:1284-1335.
17. Mufson EJ, Conner JM, Kordower JH: Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport 1995;6:1063-1066.
18. NTR gene expression in single cholinergic neurons mark the progression of Alzheimer's disease. J Neurochem 2006;97:475-487.
19. Fahnestock M, Michalski B, Xu B, Coughlin MD: The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001;18:210-220.
20. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C: Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dem Geriatr Cogn Dis 2006;21:9-15.
21. Hock C, Heese K, Müller-Spahn F, Huber P, Riesen W, Nitsch RM, Otten U: Increased CSF levels of nerve growth factor in patients with Alzheimer's disease. Neurology 2000;54:2009-2011.
22. Moser KV, Reindl M, Blasig I, Humpel C: Brain capillary endothelial cells proliferate in response to NGF, express NGF receptors and secrete NGF after inflammation. Brain Res 2004;1017:53-60.
23. Rossner S, Bakinde N, Zeitschel U, Schliebs R, Bigl V: Cerebrospinal fluid cholinesterases-markers for loss of cholinergic basal forebrain neurons? Int J Dev Neurosci 1998;16:669-673.
24. Weis C, Marksteiner J, Humpel C: Nerve growth factor and glial cell line-derived neurotrophic factor restore the cholinergic phenotype in organotypic brain slices of the basal nucleus of Meynert. Neuroscience 2001;102:129-138.
25. Humpel C, Weis C: Nerve growth factor and cholinergic CNS neurons studied in organotypic brain slices: implications in Alzheimer's disease? J Neural Transm Suppl 2002;62:253-263.
26. Maddalena A, Papassotiropoulos A, Müller-Skaper SD, Leon A: Update of the NGF saga. J Neurol Sci 1995;130:119-127.
27. Marquis JK, Volicer L, Mark KA, Direnfeld LK, Freedman M: Cholinesterase activity in plasma, erythrocytes, and cerebrospinal fluid of patients with dementia of the Alzhei mer type. Biol Psychiatry 1985;20:605-610.
28. Nakano S, Kato T, Nakamura S, Kameyama M: Acetylcholinesterase activity in cerebrospinal fluid of patients with Alzheimer's disease and senile dementia. J Neurol Sci 1986;75:213-223.
29. Mashayekhi F, Salehin Z: Cerebrospinal fluid nerve growth factor levels in patients with Alzheimer's disease. Ann Saudi Med 2006;26:278-282.
30. NTR. Am J Pathol 2005;166:533-543.
31. Dicou E, Vermersch P, Penisson-Besnier I, Dubas F, Nerriere V: Anti-NGF autoantibodies and NGF in sera of Alzheimer patients and in normal subjects in relation to age. Autoimmunology 1997:26:189-194.
32. Capsoni S, Giannotta S, Cattaneo A: Early events of Alzheimer-like neurodegeneration in anti-nerve growth factor transgenic mice. Brain Aging 2002;2:24-43.
33. Persic N, Feric F: Toxicity of cerebrospinal fluid in schizophrenia. Neuropsihijatrija 1957;5:149-156.
34. Strzalko M: Use of a simple biological test in detecting toxic properties of the cerebrospinal fluid. Neurol Neurochir Psychiatr Pol 1962;12:685-692.
35. Täuber MG, Sachdeva M, Kennedy SL, Loetscher H, Lesslauer W: Toxicity in neuronal cells caused by cerebrospinal fluid from pneumococcal and gram-negative meningitis. J Infect Dis 1992;166:1045-1050.
36. Belokurov M, Lushchilova VD: Toxicity of the cerebrospinal fluid in comas of various etiologies. Zh Nevropatol Psikhiatr Im SS Korsakova 1987;87:1781-1782.
37. Maric D, Millward JM, Ballok DA, Szechtman H, Denburg JA, Barker JL, Sakic B: Neurotoxic properties of cerebrospinal fluid from behaviorally impaired autoimmune mice. Brain Res 2001;920:183-193.
38. Sen I, Nalini A, Joshi NB, Joshi PG: Cerebrospinal fluid from amyotrophic lateral sclerosis patients preferentially elevates intracellular calcium and toxicity in motor neurons via AMPA/kainate receptor. J Neurol Sci 2005;235:45-54.
39. Hao R, Ebadi M, Pfeiffer RF: Selegiline protects dopaminergic neurons in culture from toxic factors(s) present in the cerebrospinal fluid of patients with Parkinson's disease. Neurosci Lett 1995;200:77-80.